Related Experiment Videos
[Somatostatin and somatostatin receptors in the prostate]
A A Sinisi1, A Bellastella, D Pasquali
1Dipartimento di Internistica Clinica e Sperimentale, Sezione di Endocrinologia ed Andrologia, Seconda Università degli Studi, Napoli. antonio.sinisi@unina2.it
Abstract:
Somatostatin (st) exerts a role in the control of prostate growth and function acting both at hypothalamus-hypophysis level and at glandular level. St analogues have been used to control prostate cancer (CaP) in clinical trials, with contradictory results. These data may be interpreted on the basis of st mechanism of action and tissue distribution of the five st receptors (sst1-5). Sts have been found in prostate tissue and, specifically, in the epithelial component. sst2 is preferentially expressed on normal prostate, sst1 and sst5 on CaP. st inhibits the proliferation of LNCaP and octreotide normal prostate epithelial cells in primary cultures. The lack of sst2 in CaP may explain the ineffectiveness of some selective st analogues in clinical trials. The use of other analogues actually developed with high affinities to ssts expressed mainly in CaP may represent a more rational approach.
Insights
Somatostatin (st) impacts prostate function and growth. Targeting specific somatostatin receptors (ssts) on prostate cancer (CaP) cells offers a more effective therapeutic strategy than previously thought.
Area of Science:
- Endocrinology
- Oncology
- Urology
Background:
- Somatostatin (st) plays a role in regulating prostate gland growth and function.
- Somatostatin analogues have yielded inconsistent results in clinical trials for prostate cancer (CaP).
Purpose of the Study:
- To investigate the mechanism of action of somatostatin and the distribution of its receptors (sst1-5) in prostate tissue.
- To correlate receptor expression patterns with the efficacy of somatostatin analogues in prostate cancer treatment.
Main Methods:
- Analysis of somatostatin receptor expression in normal prostate and prostate cancer tissues.
- In vitro studies assessing the effect of somatostatin on prostate epithelial cell proliferation.
Main Results:
- Somatostatin receptors (ssts) are present in prostate epithelial cells.
- sst2 is predominantly expressed in normal prostate tissue, while sst1 and sst5 are found in CaP.
- Somatostatin inhibits the proliferation of normal prostate epithelial cells.
Conclusions:
- The differential expression of somatostatin receptors in normal versus cancerous prostate tissue is critical.
- The ineffectiveness of some somatostatin analogues in clinical trials may be due to targeting sst2, which is lacking in CaP.
- Developing somatostatin analogues with high affinity for sst1 and sst5, which are expressed in CaP, represents a more rational therapeutic approach.